Osterlund started his industrial career in 2007 as group leader for mammalian cell technology at Danish biotech CRO Bioneer. After working as an in vitro pharmacologist and project leader at biotech company Zealand Pharma, he joined AstraZeneca in 2014 to support cell assay development. Four years later, he moved to Pelago Bioscience, a Swedish CRO. In 2019, he was appointed head of cell biology at Confo Therapeutics, based in Ghent, Belgium. Osterlund studied Biochemistry and Molecular Biology (MSc) at the University of Odense (Denmark), and he holds a PhD in Cell and Molecular Biology from Lund University (Sweden).

Toxys B.V. offers a broad spectrum of in vitro toxicology solutions. The biotech company was founded in 2014 as a spin-off from the Leiden University Medical Center.